HOME >> MEDICINE >> NEWS
Randomized trial of two therapies for acute lymphocytic leukemia finds survival advantage

Orlando, May 16, 2005 -- A prospective, randomized trial comparing a novel regimen with a standard treatment for adult patients with acute lymphocytic leukemia (ALL) showed a distinct advantage that continued to show superior results at three-, four-, and five-year intervals in the investigational arm of the trial. The drugs were given as induction therapy, an initial chemotherapy treatment with the goal of putting a patient's leukemia into complete remission. Patients who received the investigational regimen, comprised of cytarabine with high-dose mitoxantrone, also experienced a higher frequency of complete remission compared with patients on a standard, vincristine plus prednisone-based regimen. Mark A. Weiss, MD, a leukemia specialist at Memorial Sloan-Kettering Cancer Center and lead author of the eight-year, multicenter study, presented the study results today at the annual meeting of the American Society for Clinical Oncology.

"There have been very few randomized trials in adult ALL. This is probably the first study in 20 years that focuses on induction therapy, and it appears to show that one treatment is superior to another in putting the disease in remission," explained Dr. Weiss. "Although the survival rates for these patients were initially similar in both arms, the results diverged after two years. Patients treated with cytarabine plus high-dose mitoxantrone appeared to have a survival advantage at three, four, and five years. The difference in survival rates seemed even more pronounced for the subset of ALL patients with the Philadelphia chromosome, a genetic predisposition that makes the disease more difficult to treat," he said.

The trial looked at two regimens to be used as induction therapy. One hundred and sixty-four patients with ALL, who were able to participate in the trial, were randomized to receive either a standard regimen (L-20) of vincristine, prednisone, cyclophosphamide, and doxorubicin or the ALL-2 regimen of cytara
'"/>

Contact: Joanne Nicholas
nicholaj@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
16-May-2005


Page: 1 2 3

Related medicine news :

1. Randomized study indicates that patients with herniated disk improved with or without surgery
2. Randomized trial in Zimbabwe suggests how to make HIV testing and counselling attractive
3. New contracts support clinical trials on antibiotic-resistant, community-acquired staph infections
4. Warfarin better than aspirin at stroke prevention in elderly people with atrial fibrillation
5. Helicopter flight trials for EGNOS
6. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
7. GSK announces launch of largest ever Phase III trial in lung cancer treatment
8. Bias in statin trials, failure to control malaria, and more
9. International journal group updates guidelines on registration of clinical trials
10. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
11. Childrens Hospital and Pitt lead national trial of hypothermia to treat pediatric brain injury

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
Breaking Medicine Technology:
Cached News: